Protocol Ledger

Academic / Cooperative Group · Consolidated Sponsor Hub

MD Anderson Cancer Center: Clinical Trials & FDA Approval Profile

MD Anderson Cancer Center (Houston, TX) sponsors 519 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 344 active protocols (201 recruiting now), 38 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)26.4%
Median Closed Enrollment vs National (145 pts)24 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for MD Anderson Cancer Center
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)519
Active Pipeline (Recruiting Now)344 (201)
Completed vs Stopped Early38 / 137 (26.4%)
Median Closed Actual Enrollment24 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With MD Anderson Cancer Center
Hospital Research SiteLocationShared Protocols
MD Anderson Cancer CenterHouston, TX481
Dana-Farber Cancer InstituteBoston, MA9
Memorial Sloan Kettering Cancer CenterNew York, NY6

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by MD Anderson Cancer Center
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT03583710Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk ofPhase IIIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for MD Anderson Cancer Center across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the MD Anderson Cancer Center Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI